Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603246 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
A Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 7
- Study locations
NCT06603246: Recruiting Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis, sponsored by Genentech.
NCT06603246 is a Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis that is actively recruiting participants, run by Genentech. The registered enrollment target is 128 participants, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603246, a Phase 1 study of Chronic Obstructive Pulmonary Disease and Non-cystic Fibrosis Bronchiectasis, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Primary Outcome
The AEs will be graded according to the DAIDS table for grading the severity. The severity level is graded from Grade 1 (mild) to 4 (Potentially Life-Threatening).
Conditions Studied
Interventions
- DRUG GDC-6988
Study Locations (7)
Alabama
- University of Alabama at Birmingham - Birmingham
- Accel Research Site - Achieve - Birmingham - ERN - PPDS - Vestavia Hills
California
- Stanford Center for Excellence in Pulmonary Biology - Palo Alto
Kansas
- University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd - Kansas City
North Carolina
- University of North Carolina Clinical Research Center - Chapel Hill
Pennsylvania
- UPMC Montefiore Hospital - Pittsburgh
Texas
- TTS Research - Boerne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2027-11-15 |
| Phase | Phase 1 |
What NCT06603246 shows while recruiting
NCT06603246 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which GDC-6988 is the first listed.
NCT06603246 lists 7 locations in 6 states (Alabama, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT06603246 about?
NCT06603246 is a clinical study titled "A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease". This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
What is the current status of trial NCT06603246?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-11-18. Estimated completion is 2027-11-15.
What conditions does trial NCT06603246 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis.
What interventions are being tested in trial NCT06603246?
The interventions under investigation include: GDC-6988 (DRUG).
Who is sponsoring clinical trial NCT06603246?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603246 being conducted?
This trial has 7 study locations across Alabama, California, Kansas, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06603246's enrollment target sits among peer trials
128 45th of 86 higher than 42 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of Semaglutide in Advanced Lung Disease
RECRUITING · Phase 1
-
Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 1
-
Mindfulness Based Stress Reduction in COPD
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI